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Multiple targeted therapies are currently explored for pediatric and young adult B-cell
precursor acute lymphoblastic leukemia (BCP-ALL) treatment. However, this new
armamentarium of therapies faces an old problem: choosing the right treatment for each
patient. The lack of predictive biomarkers is particularly worrying for pediatric patients
since it impairs the implementation of new treatments in the clinic. In this study, we used
the functional assay dynamic BH3 profiling (DBP) to evaluate two new treatments for
BCP-ALL that could improve clinical outcome, especially for relapsed patients. We found
that the MEK inhibitor trametinib and the multi-target tyrosine kinase inhibitor sunitinib
exquisitely increased apoptotic priming in an NRAS-mutant and in a KMT2A-rearranged
cell line presenting a high expression of FLT3, respectively. Following these observations,
we sought to study potential adaptations to these treatments. Indeed, we identified with
DBP anti-apoptotic changes in the BCL-2 family after treatment, particularly involving
MCL-1 – a pro-survival strategy previously observed in adult cancers. To overcome this
adaptation, we employed the BH3 mimetic S63845, a specific MCL-1 inhibitor, and
evaluated its sequential addition to both kinase inhibitors to overcome resistance. We
observed that the metronomic combination of both drugs with S63845 was synergistic
and showed an increased efficacy compared to single agents. Similar observations were
made in BCP-ALL KMT2A-rearranged PDX cells in response to sunitinib, showing an
analogous DBP profile to the SEM cell line. These findings demonstrate that rational
sequences of targeted agents with BH3 mimetics, now extensively explored in clinical
trials, may improve treatment effectiveness by overcoming anti-apoptotic adaptations in
BCP-ALL.
Keywords: pediatric leukemia, targeted therapies, resistance, apoptosis, BH3 mimetics
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) is characterized by
uncontrolled growth of lymphoid cells and it accounts for
25% of all pediatric cancers (Howlader et al., 2015). Three
out of four cases of pediatric ALL are caused by B-cell
precursors, also named BCP-ALL (Schwab and Harrison,
2018). BCP-ALL diagnosed patients are typically treated with
a chemotherapeutic combination of vincristine, asparaginase,
a corticosteroid (prednisone or dexamethasone) and an
anthracycline (doxorubicin or daunorubicin), and most patients
achieve a complete remission (PDQ Pediatric Treatment
Editorial Board, 2002). Despite this outstanding treatment
effectiveness, around 15–20% of patients relapse (Locatelli et al.,
2012) causing an overall survival rate of 90% (O’Brien et al.,
2018). And because of its high incidence this type of tumor
is still the deadliest pediatric cancer. Relapsed and refractory
patients (R/R) that fail to achieve a complete remission, present
highly resistant tumors forcing clinicians to use more aggressive
and highly toxic treatments (Oskarsson et al., 2018). Even those
patients that are cured face long-term secondary effects including
mental problems, functional impairment, cardiotoxicity and
increased morbidity (Mody et al., 2008). There is a clear need for
new treatments to enhance tumor elimination while reducing
lasting toxicity.
Important efforts have been made to identify and characterize
oncogenic molecular targets to block them and impair tumor
growth and progression. Since the first successes treating
pediatric ALL patients using folic acid antagonists achieved by
Sydney Farber in the late 1940s (Miller, 2006), a myriad of
compounds targeting multiple proteins have been explored in
clinical trials. The first and most successful targeted therapy
approved for hematological malignancies was imatinib for adult
chronic myelogenous leukemia (Deininger, 2008). Interestingly,
imatinib targets the BCR-ABL fusion protein that is also
present in the Philadelphia chromosome-positive (Ph +) B-cell
acute lymphoblastic leukemia (B-ALL) subtype. Clinical trials
evaluating imatinib and dasatinib for pediatric and young adult
Ph+ B-ALL showed improvement in treatment response (Biondi
et al., 2012; Gore et al., 2018). Besides BCR-ABL fusion protein,
JAK/STAT pathway proteins, FLT3 receptor, MAPK pathway
proteins, precursor-B-cell receptor (pre-BCR) or the ubiquitin-
proteasome system have been proposed as potential targets for
different B-ALL subtypes, increasing the armamentarium of
potential targeted therapies for this disease (Kuhlen et al., 2019).
Identifying new effective treatments for pediatric cancer is
challenging. If these therapies are not correctly assigned, there is
a risk to provoke undesired secondary effects. Precision medicine
aims to correctly assign effective treatments to every patient
based on molecular characterization of the tumor (Jameson and
Longo, 2015). Its successful implementation will lead to more
effective therapeutic regimes and reduce side effects (Mathur
and Sutton, 2017). Genetic analyses are the most common
strategy used to identify cancer patients that would benefit from
targeted therapies (Malone et al., 2020). However, the pediatric
population presents a low number of mutations compared
to adult population, making difficult to identify predictive
biomarkers (Savary et al., 2020). In contrast, functional assays
overcome these drawbacks by directly exposing patient-isolated
tumor cells to different treatment options and measuring their
effectiveness (Howard et al., 2017). Yet, this approach presents a
major limitation: primary cells rapidly decay, lose their viability
and experience phenotypic changes, preventing their use in
prolonged assays (Meijer et al., 2017). In this regard, the
functional assay dynamic BH3 profiling (DBP) (Montero et al.,
2015) can identify effective anti-cancer treatments in less than
24 h directly on patient samples.
Most anti-cancer agents engage cell death by apoptosis,
a process regulated by the BCL-2 family of proteins. Inside
this family, BAX and BAK are considered effector members
and once activated, oligomerize to form pores and induce
the Mitochondrial Outer Membrane Permeabilization (MOMP)
which represents the point of no return for the apoptotic
process (Wei et al., 2001) and the cell commitment to die
(Letai, 2011). MOMP induces the release of cytochrome c (and
other proteins) from the mitochondria into the cytosol, and its
binding to APAF-1 and caspase-9 form the apoptosome, which
activates downstream effector caspases and executes apoptosis.
Effector proteins are activated by proteins presenting a unique
BCL-2 homology (BH) domain, known as BH3-only activator
proteins (BIM, BID, and PUMA). The anti-apoptotic BCL-2
family proteins (BCL-2, BCL-xL, MCL-1, BCL-w, and BFL-1) can
inhibit both effectors and activator members, hence protecting
cells from apoptosis. A fourth subgroup of BCL-2 family proteins,
the sensitizers – that include BAD, HRK and NOXA among
others – exert a pro-apoptotic effect by specifically inhibiting the
anti-apoptotic proteins (Letai et al., 2002).
Dynamic BH3 profiling uses synthetic peptides that mimic
the BH3 domain of the pro-apoptotic BH3-only, with a similar
effect as the full-length protein. It uses these peptides to measure
how close cells are to commit apoptosis, or how “primed” are for
death, after a short incubation with the treatment. DBP has been
extensively used to identify effective anti-cancer treatments in cell
lines, patient-derived xenografts (PDX) and directly on patient-
isolated cells from different types of cancer (Montero et al., 2015,
2017, 2019; Wu et al., 2015; Townsend et al., 2016; Deng et al.,
2017; Alcon et al., 2020) with an excellent predictive capacity.
Interestingly, using sensitizer-analog BH3 peptides, DBP can
identify the anti-apoptotic protein used by cancer cells to survive
therapy (Frenzel et al., 2009; Montero and Letai, 2018). In fact,
most cytogenetic abnormalities found in BCP-ALL regulate anti-
apoptotic BCL-2 proteins. For example, the BCR-ABL fusion
protein upregulates BCL-2 and ETV6/RUNX1 promotes BCL-xL
overexpression (Brown et al., 2017). Hereof, BH3 mimetics, anti-
apoptotic inhibitors widely explored in clinical trials, can be used
to overcome this therapy-acquired resistance. In fact, it has been
demonstrated in ALL that combining standard-of-care treatment
with BH3 mimetics can greatly increase efficacy (Ni Chonghaile
et al., 2014; Iacovelli et al., 2015; Khaw et al., 2016; Seyfried et al.,
2019). But the key question remains unsolved: how and when to
better utilize them in the clinic.
Here, we use DBP to identify new effective therapeutic
strategies for pediatric and adolescent BCP-ALL. We tested
two promising targeted therapies, trametinib (MEK inhibitor)
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and sunitinib (multi-target tyrosine kinase inhibitor), currently
explored in pre-clinical studies. We found that both caused an
MCL-1 dependence to protect BCP-ALL cells from apoptotic cell
death and that its inhibition with a BH3 mimetic significantly
enhanced leukemia cell death. Finally, we were able to observe
similar anti-apoptotic adaptations in a pediatric BCP-ALL PDX,
demonstrating its potential use in the clinic.
MATERIALS AND METHODS
Cell Lines and Treatments
NALM-6 and SEM cell lines were kindly provided by Prof. PM
laboratory at the Josep Carreras Leukaemia Research Institute.
Both cell lines were cultured in RPMI 1640 medium (31870,
Thermo Fisher, Gibco, Paisley, Scotland) with 10% of heat-
inactivated fetal bovine serum (10270, Thermo Fisher, Gibco),
1% of L-glutamine (25030, Thermo Fisher, Gibco) and 1% of
penicillin/streptomycin (15140, Thermo Fisher, Gibco). Cells
were maintained inside a humidified incubator at 37◦C and 5%
of CO2. Imatinib, dasatinib, sunitinib, trametinib, ibrutinib and
ruxolitinib were purchased at SelleckChem (Munich, Germany)
and ABT-199, A-1331852 and S63845 were purchased at
MedChemExpress (Monmouth Junction, NJ, United States).
These reagents were diluted in dimethyl sulfoxide (DMSO)
(D8418, Sigma-Aldrich, Saint Louis, MO, United States) and
added to the culture media at the indicated concentration and
incubation time for every experiment.
Cell Death Assay
After treatment, cells were resuspended in staining buffer
(100 mM HEPES free acid, 40 mM KCl, 1.4 M NaCl, 7.5 mM
MgCl2 and 25 mM CaCl2 at pH 7.4) with Alexa Fluor
647 R© conjugated Annexin V (640912, BioLegend) and DAPI
(62248, Thermo Fisher). Cells were analyzed with a Gallios flow
cytometer (Beckman Coulter, Nyon, Switzerland) and results
were analyzed with FlowJo software to quantify viable cells
(Annexin V and DAPI negative events). Results were represented
as the mean of %Cell death (100-%viable cells) of at least three
independent experiments.
Dynamic BH3 Profiling
Dynamic BH3 profiling (DBP) was performed as previously
described (Ryan et al., 2016; Montero et al., 2019; Alcon
et al., 2020). After treatment, cells were stained using the
viability marker Zombie Violet (423113, BioLegend, Koblenz,
Germany) for 10 min at room temperature, washed with PBS and
resuspended in 330 µL of MEB buffer (150 nM mannitol, 10 mM
HEPES-KOH pH 7.5, 150 mM KCl, 1 mM EGTA, 1 mM EDTA,
0.1% BSA and 5 mM succinate). In parallel, peptide solutions
were prepared using MEB buffer with 0.002% of digitonin (D141,
Sigma-Aldrich) and 12 different peptide solutions with final
concentrations of 25 µM of alamethicin (BML-A150-0005, Enzo
Life Sciences, Lörrach, Germany), 10 µM, 3 µM, 1 µM, 0.3 µM,
0.1 µM, 0.03 µM, and 0.01 µM of BIM BH3 peptide, 0.1 µM
of BAD BH3 peptide, 100 µM of HRK BH3 peptide, 10 µM of
MS1 BH3 peptide and a DMSO only control. A 25 µL of cells was
added to 25 µL of each peptide solution in a 96-well plate (3795,
Corning, Madrid, Spain) and incubated at room temperature for
1 h. After this incubation, cells were fixed with 25 µL of an 8%
paraformaldehyde solution for 15 min and neutralized with 50 µL
of N2 buffer (1.7 M tris base, 1.25 M glycine at pH 9.1). Finally,
25 µL of intracellular staining buffer (1% Tween20, 5% BSA in
PBS) with 1:1,000 dilution of the cytochrome C antibody (Alexa
Fluor R© 647 anti-Cytochrome c—6H2.B4, 612310, BioLegend)
was added and plates were incubated overnight at 4◦C. Results
were analyzed using a Sony flow cytometer (SONY SA3800,
Surrey, United Kingdom) and processed with FlowJo to quantify
cytochrome c release (%priming). 1%priming stands for the
difference of %priming between non-treated cells and treated
cells for every specific peptide. All results are represented as the
mean of at least three independent experiments.
Protein Extraction
After treatment, cells were collected and washed with PBS.
Then, cells were resuspended in RIPA buffer [150 mM NaCl,
5 mM EDTA, 50 mM Tris–HCl pH = 8, 1% Triton X-100, 0.1%
SDS, EDTA-free Protease Inhibitor Cocktail (4693159001, Roche,
MannKind, Germany)] and lysed for 30 min on ice following
centrifugation at 4◦C for 10 min at 16,000g. Protein in the
supernatant was quantified using PierceTM BCA Protein Assay
Kit (23227, Thermo Fisher) and stored at−20◦C.
Immunoprecipitations
Lysates were obtained following the protein extraction protocol
but using immunoprecipitation (IP) lysis buffer (150 mM NaCl,
10 mM Hepes, 2 mM EDTA, 1% Triton X-100, 1.5 mM
MgCl2, 10% glycerol and EDTA-free Protease Inhibitor Cocktail
(4693159001, Roche, MannKind, Germany). Again, the protein
extracted was quantified with PierceTM BCA Protein Assay
Kit and stored at −20◦C. Equivalent amount of protein was
incubated at 4◦C overnight with magnetic beads (161-4021,
Bio-Rad, Madrid, Spain) previously conjugated to 5 µg of
rabbit anti-MCL-1 antibody (CST94296, Cell Signaling, Leiden,
Netherlands) or 5 µg of rabbit-IgG antibody (CST2729, Cell
Signaling). A 30 µL of protein for each condition was stored
at −20◦C as the input fraction. After incubation, tubes were
magnetized to obtain the binding fraction. The supernatant was
extracted and stored at −20◦C as the unbound fraction. The
binding fraction was cleaned with PBS-T (PBS with 0.1% Tween
20) and resuspended in 40 µL of 4× Laemmli sample buffer
(161-0747, Bio-Rad), then heated at 70◦C to allow separation
between the target protein and the magnetic beads-antibody
complex. The sample was magnetized again and the supernatant
containing the pulled-down proteins was stored at −20◦C
as IP fractions.
Immunoblotting
An equal amount of protein was prepared in 4× Laemmli buffer
(161-0747, Bio-Rad) and heated at 96◦C for 10 min. The sample
was loaded in an SDS-PAGE gel (456-1025, Bio-Rad) and proteins
were separated for 2 h. Then, proteins were transferred to a
PVDF membrane (10600023, Amersham Hybond, Pittsburgh,
PA, United States) at 55V for 2 h at 4◦C. The membrane was
blocked with 5% dry milk in TBS-T (50 mM Tris–HCl pH = 7.5,
150 mM NaCl and 1% Tween20) for 1 h and washed with
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TBS-T. After blocking, the membrane was probed overnight
at 4◦C in TBS-T with 3%BSA and 1:1,000 dilution of the
primary antibody against the protein of interest: rabbit anti-BCL-
2 (CST4223, Cell Signaling), rabbit anti-BCL-xL (CST2764, Cell
Signaling), rabbit anti-MCL-1 (CST5453, Cell Signaling), rabbit
anti-BIM (CST2933, Cell Signaling), rabbit anti-BAX (CST2772,
Cell signaling), rabbit anti-BAK (CST12105, Cell signaling),
phospho-p44/42 MAPK (Erk1/2) (Thr202/Thr204) (CST4370,
Cell signaling), phospho-BIM (Ser69) (CST4585, Cell signaling)
and rabbit anti-Actin (CST4970, Cell Signaling) followed by 1 h
at room temperature with 1:3,000 of anti-rabbit IgG HRP-linked
secondary antibody (CST7074, Cell Signaling). When necessary,
membranes were stripped using mild stripping buffer (0.1 M
glycine pH 2.5 and 2% SDS) for two cycles of 20 min at 50◦C
and extensively washed with TBS (50 mM Tris–HCl pH = 7.5
and 150 mM NaCl). Membranes were developed using Clarity
ECL Western substrate (1705060, Bio-Rad) in a LAS4000 imager
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Bands were
quantified using ImageJ software to measure the integrated
optical density.
Precursor BCP-ALL PDX Model
Generation
The primary leukemia specimen was obtained from peripheral
blood of an infant patient with newly diagnosed pro-B ALL
after informed written consent with the legal guardians and in
accordance with the institution’s ethical review board. Xenograft
cells were established by intravenous injection of ALL cells into
female NOD/SCID mice (NOD.CB17-Prkdcscid, Charles River)
as described earlier (Meyer et al., 2011; Seyfried et al., 2019).
Animal experiments were approved by the appropriate authority
(Tierversuch Nr. 1260, Regierungspräsidium Tübingen).
DBP With PDX Cells
After treatment, cells were stained using the viability marker
Zombie Violet (423113, BioLegend, Koblenz, Germany) for
10 min on ice, followed by staining for 30 min on ice with
1:200 dilution of Alexa Fluor R© 488 anti-human CD45 antibody
(368536, BioLegend) and PE anti-human CD19 antibody
(392506, BioLegend) in TBS with 10%FBS. Then, cells were
washed with PBS and resuspended in 330 µL of MEB buffer. After
this, DBP was done as explained in point 2.3.
Statistical Analysis
For the ROC curve analysis, data sets were separated as
responders (cell death >10%) and non-responders (cell death
<10%) and their corresponding values of 1%priming were used
to perform the analysis. Synergies were calculated using the
Bliss Independent model (Foucquier and Guedj, 2015) were the
Combination Index (CI) is calculated as CI = (CDA + CDB –
CDA∗CDB)/CDcombination (CD stands for the percentage of
cell death after treatment A, B or the combination of them).
Combinations with CI < 1 were considered synergistic.
GraphPad Prism 9 was used to perform statistical analyses and
generate graphs.
RESULTS
DBP Predicts Cytotoxicity in BCP-ALL
Cell Lines
Targeted therapies are currently explored in clinical trials to treat
pediatric and young adult BCP-ALL. For example, imatinib and
dasatinib for patients presenting the BCR-ABL fusion protein
(Ph + cases); trametinib for RAS-mutant patients (Jerchel et al.,
2018); sunitinib for cases with overexpression or activating
mutations of FLT3 (Brown et al., 2005); ruxolitinib for tumors
with constitutive activation of the JAK/STAT signaling pathway
(Ding et al., 2018), and ibrutinib when pre-BCR is active (Kim
et al., 2017). We sought to explore the effects of these targeted
therapies, particularly on the apoptotic pathway, in BCP-ALL.
To explore the pro-apoptotic effect of these therapies, we
performed DBP in two pediatric and young adult cell lines,
SEM (presenting KMT2A-rearrangement and high expression of
FLT3) and NALM-6 (NRAS-mutant), respectively (Figure 1A).
After a short incubation with treatments, we observed that
sunitinib induced a high increment in apoptotic priming when
exposed to the BIM peptide in the SEM cell line, while
trametinib increased it mildly in both cell lines. In contrast,
imatinib, dasatinib, ruxolitinib and ibrutinib did not produce
any induction of apoptosis (Figure 1B). To validate DBP’s
predictions, we treated these cells for longer timepoints with
the same therapies and assessed cell death induction. When
comparing 1%priming and cytotoxicity, similarly to DBP’s
predictions, we observed that sunitinib in the SEM cell line and
trametinib in both cell lines were more efficient than the rest
of the therapies inducing cell death (Figure 1C). The receiver
operating characteristic curve analysis was then used to assess the
predictive capacity of DBP on identifying cytotoxic treatments.
Our results showed an area under the curve of 1, confirming
that DBP is an excellent predictor for this experimental subset
(Supplementary Figure 1A). Furthermore, 1%priming strongly
correlated with cell death after 3 days of treatment, suggesting
that a higher increase in apoptotic priming is an early predictor
for cytotoxicity in these cells (Supplementary Figure 1B).
Altogether, these results demonstrate that DBP could be used as a
predictive biomarker to find effective therapies for BCP-ALL.
Trametinib Induces MCL-1 Dependence
in NALM-6 Cell Line
As previously mentioned, trametinib was the only targeted
therapy tested that showed some efficacy in NALM-6 cells.
However, only 20% of the cells were dead after 72 h of treatment,
showing a modest efficacy. Multiple studies previously reported
cancer cells’ adaptation to therapy and the key role of the anti-
apoptotic BCL-2 family proteins in their resistance to cell death
(Reed et al., 1996; Mansoori et al., 2017; Maji et al., 2018;
Wei et al., 2020). We next sought to study the role of these
proteins after trametinib treatment on NALM-6. We repeated
the DBP analyses, but instead of using the BIM BH3 peptide,
we used peptides mimicking the sensitizer members of the
BCL-2 family to specifically identify the anti-apoptotic proteins’
contribution. In this case, we used a low concentration of the
Frontiers in Cell and Developmental Biology | www.frontiersin.org 4 September 2021 | Volume 9 | Article 695225
fcell-09-695225 September 2, 2021 Time: 13:5 # 5
Manzano-Muñoz et al. MCL-1 Inhibition Overcomes BCP-ALL Resistance
FIGURE 1 | Cytotoxicity induced by targeted drugs in BCP-ALL cell lines. (A) Graphical scheme of the DBP technique where cancer cells are plated and treated for
16 h. After drug exposure, cells are plated in 96-well plates and exposed to the different BH3 peptides. After 1 h, cells were fixed and stained with an
anti-Cytochrome C antibody overnight. Finally, analyses were performed using a flow cytometer for drug-response curves. Designed with BioRender.com. (B) DBP
with BIM BH3 peptide after 16 h of incubation with 1,000 nM imatinib, 100 nM dasatinib, 1,000 nM sunitinib, 100 nM trametinib, 100 nM ruxolitinib, and 1,000 nM
ibrutinib in NALM-6 and SEM cell lines. 1%priming stands for the difference in %priming between treatment and control conditions. (C) Cytotoxicity expressed as
percentage of dead cells after 72 h of treatment with the same therapies assessed by Annexin V/DAPI staining. All results are expressed as the mean ± standard
error of the mean (SEM) of at least three biologically independent replicates. Statistical significance was calculated using Student’s t-test comparing to control
condition and considering *p < 0.05 and **p < 0.01.
BAD BH3 peptide, due to the exquisite sensitivity of both BCP-
ALL cell lines to this peptide. In brief, an increase in apoptotic
priming after incubation with BAD BH3 peptide would mean
that BCL-2 and perhaps BCL-xL are involved in cell resistance
to trametinib. Similarly, a gain in apoptotic priming with HRK
BH3 would indicate an enhanced BCL-xL contribution, while
an MS1 BH3 signal increase would point to MCL-1. When we
analyzed NALM-6 treated with trametinib, we observed a positive
signal from all sensitizer peptides (Figure 2A), suggesting that
multiple anti-apoptotic proteins may be involved in cell survival
after therapy. We next studied how to overcome this acquired
resistance by preincubating the cells with trametinib and then
adding specific BH3 mimetics – small molecules that specifically
block anti-apoptotic proteins. When we sequentially combined
trametinib with the BCL-2 inhibitor ABT-199 (venetoclax), the
BCL-xL inhibitor A-1331852 or the MCL-1 inhibitor S63845, we
observed enhanced cytotoxicity in all the combinations tested
compared to single agent treatment. However, the dual inhibition
of MEK and MCL-1 was significantly more effective and clearly
synergistic (CI = 0.28), achieving almost a complete elimination
of these cells (Figure 2B).
We next examined the molecular mechanism behind the
strong trametinib and S63845 synergy. The BCL-2 family of
proteins is a complex interactome, thus explaining the observed
effectiveness could be challenging. It is well reported that
trametinib treatment leads to an increase of the activator
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FIGURE 2 | Trametinib synergizes with S63845 in NALM-6 cells, increasing BIM and MCL-1 protein expression. (A) DBP results using sensitizer peptides to study
anti-apoptotic dependence of BCL-2 and BCL-xL with BAD 0.1 µM, BCL-xL with HRK 100 µM and MCL-1 with MS1 10 µM after 16 h of incubation with trametinib
100 nM in NALM-6 cell line. (B) Cytotoxicity was assessed by Annexin V/DAPI staining after 96 h incubation with trametinib 100 nM, ABT-199 100 nM, A-1331852
100 nM and S63845 1,000 nM in NALM-6 cell line. BH3 mimetics in combination with trametinib were added 16 h after treatment. (C) Western blot analysis for
anti-apoptotic and BIM proteins in NALM-6 cells after 16 h of treatment with trametinib 100 nM. Quantification of optical density for each protein was normalized to
actin, and fold-change was calculated comparing to protein expression in the control condition. All results are expressed as the mean ± standard error of the mean
(SEM) of at least three biologically independent replicates. Statistical significance was calculated using Student’s t-test compared to control condition and
considering *p < 0.05 and **p < 0.01. Significance was also calculated comparing combination conditions with both single agents and considering #p < 0.05 and
##p < 0.01. Combination Index (CI) is indicated on top of every combination where CI < 1 indicates synergy.
BIM, which was also detected in the NALM-6 cell line
(Figure 2C). MEK inhibition using trametinib caused a
reduction of ERK1/2 phosphorylation, that also reduced BIM
phosphorylation (Supplementary Figure 2A), and avoided its
proteasomal degradation (O’Reilly et al., 2009). This increase
in BIM causes priming for apoptosis, yet the anti-apoptotic
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members of the BCL-2 family could sequester this protein
and block the initiation of apoptosis. When we analyzed the
anti-apoptotic proteins expression, we found that this MEK
inhibitor selectively promoted MCL-1 increase, while BCL-2
and BCL-xL levels remained unchanged (Figure 2C). In the
case of the effector proteins, BAX was not detected in this
cell line and BAK slightly increased after trametinib treatment
(Supplementary Figure 2B). To confirm that MCL-1 is the main
protein binding to BIM, we decided to immunoprecipitate it
and study their interaction. MCL-1 was detected in the normal
rabbit-IgG unbound fraction but not in the anti-MCL-1 antibody
condition (Figure 3A), confirming that we were able to effectively
pull it down. As previously observed, trametinib treatment
caused an increased binding of MCL-1 with BIM, and S63845
caused a marked increase in MCL-1 (Figure 3B) due to protein
stabilization, as described elsewhere (Kotschy et al., 2016; Li et al.,
2019; Montero et al., 2019). As expected, the interaction between
MCL-1 and BIM in the IP fraction increased when treated with
trametinib compared to control, and was almost completely
displaced when S63845 was sequentially added (Figure 3C).
These findings confirm MCL-1 as the main pro-survival protein
and correlate with the observed synergy (Figure 2B).
MCL-1 preferentially blocks the increase of BIM protein
after trametinib exposure, and when sequentially inhibited with
the BH3 mimetic S63845, over 80% of the cells succumbed to
this synergistic combination (Figure 2B). Interestingly, when
we combined trametinib with ABT-199 or A-1331852 only a
modest cytotoxic effect was observed (Figure 2B). Based on these
findings, we conclude that MCL-1 is the main anti-apoptotic
protein against trametinib-induced apoptosis in NALM-6, and
that BCL-2 and BCL-xL play a minor role.
Combination of Low-Dose Sunitinib and
BH3 Mimetics Synergize to Maintain
Treatment Efficacy
Secondary effects resulting from anti-cancer therapy
are particularly threating for the pediatric population
FIGURE 3 | Synergy of trametinib and S63845 in NALM-6 is explained by an increased interaction between MCL-1 and BIM. (A) Western blot analysis of the
unbound fraction after MCL-1 immunoprecipitation. (B) Immunodetection of MCL-1 and BIM initial expression in cell lysates after 16 h of incubation with trametinib
100 nM, and 2 h of incubation with S63845 1,000 nM in the specified conditions. Quantification of optical density for each protein was normalized to actin and
fold-change was calculated comparing to protein expression in the control condition. (C) Western blot of the immunoprecipitated fraction was used to study the
interaction between MCL-1 and BIM after treatment with trametinib 100 nM and 2 h with S63845 1,000 nM. To quantify this binding, BIM optical density was
normalized to MCL-1 optical density and fold-change was calculated comparing to protein expression in the control condition. All results are expressed as the
mean ± SEM of at least three biologically independent replicates. Statistical significance was calculated using Student’s t-test compared to control condition and
considering *p < 0.05 and **p < 0.01.
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(Sarosiek et al., 2017). As a result, there is a trend to substitute
high-dose single agent treatment for low-dose combinations
targeting different vulnerabilities to maximize efficacy and
reduce toxicity (Satti, 2009). In this regard, we sought to find
a combination with BH3 mimetics that could synergize with
sunitinib, currently explored in pre-clinical investigations for
adult and pediatric BCP-ALL (Brown et al., 2005; Griffith
et al., 2016). In the SEM cell line, sunitinib, administered as a
FIGURE 4 | Sunitinib synergizes with ABT-199 and S63845 in SEM cells but anti-apoptotic proteins are downregulated. (A) DBP results using sensitizers peptides to
study anti-apoptotic dependence of BCL-2 and BCL-xL with BAD 0.1 µM, BCL-xL with HRK 100 µM and MCL-1 with MS1 10 µM after 16 h of incubation with
sunitinib 1,000 nM in SEM cell line. (B) Cytotoxicity assessed by Annexin V/DAPI staining after 96 h of sunitinib 100 nM, ABT-199 10 nM, A-1331852 100 nM and
S63845 100 nM exposure in SEM cells. BH3 mimetics in combination with sunitinib were added 16 h after treatment. (C) Western blot analysis for anti-apoptotic
and BIM proteins in SEM cells after 16 h of treatment with sunitinib 100 nM and sunitinib 1,000 nM. Quantification of optical density for each protein was normalized
to actin, and fold-change was calculated comparing to protein expression in the control condition. All results are expressed as the mean ± SEM of at least three
biologically independent replicates. Statistical significance was calculated using Student’s t-test compared to control condition and considering *p < 0.05 and
**p < 0.01. Significance was also calculated comparing combination conditions with both single agents and considering #p < 0.05 and ##p < 0.01. CI is indicated
on top of every combination where CI < 1 indicates a synergistic combination.
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single agent, killed around 60% of the cells (Figure 1C), but we
aimed to improve its efficacy. By performing DBP analyses, we
found that sunitinib incubation, enhanced BAD, HRK and MS1
sensitizer BH3 peptides priming, also suggesting a diversified
anti-apoptotic adaptation to this targeted therapy (Figure 4A).
We then explored reducing 10-fold the concentration of
sunitinib, aiming to diminish the potential secondary effects
in the clinic, and combining with BH3 mimetics to boost
its anti-cancer efficacy. Two BH3 mimetics, ABT-199 and
S63845, also induced high levels of cytotoxicity as single agents
(Supplementary Figure 3), but were innocuous when lowering
10-fold their concentration (Figure 4B). To improve the
performance of the low-dose sunitinib treatment, we combined
it with three BH3 mimetics targeting different anti-apoptotic
proteins. As anticipated by DBP, when blocking any of the three
anti-apoptotic proteins studied following sunitinib treatment,
we found a significant increase in cytotoxicity. This synergistic
effect was especially notable when combining it with low-dose
ABT-199 (CI = 0.73) or S63845 (CI = 0.74) (Figure 4B).
We hypothesized that the molecular mechanism explaining
these combinations could be similar to the one found in NALM-6
after trametinib administration. Similarly, we observed a marked
increase in BIM expression after sunitinib treatment (Figure 4C),
as previously described for other types of tumors (Yang et al.,
2010). Interestingly, sunitinib also reduced ERK1/2 and BIM
phosphorylation (Supplementary Figure 4A), suggesting that
this inhibitor also affects MAPK pathway, as previously described
for other cancer types (Chahal et al., 2010; Fenton et al., 2010).
Sunitinib clearly increases apoptotic priming in the SEM cell line;
yet, it also activates the anti-apoptotic machinery to neutralize
the increase of pro-apoptotic proteins. When we analyzed the
BCL-2 family components, in contrast to what we observed in
NALM-6, there was a minor decrease in BCL-2 and a significant
reduction of MCL-1 expression (Figure 4C). No significant
changes were observed for BAX and BAK (Supplementary
Figure 4B). Surprisingly, these results seemed to antagonize the
observed synergies with ABT-199 or S63845.
As already mentioned, when exposed to a perturbation like
a cytotoxic agent, cancer cells may adapt using anti-apoptotic
proteins. However, in this case, a counterintuitive decrease in
these proteins was detected. To further elucidate how SEM cells
survive sunitinib, we immunoprecipitated MCL-1 (Figure 5A) to
study its interaction with BIM. As expected, cell lysates showed a
significant lower expression of MCL-1 and an increase in BIM
after sunitinib treatment, and the stabilization of MCL-1 after
S63845 (Figure 5B). Interestingly, we observed that sunitinib
treatment, even if the overall MCL-1 expression decreased,
promoted and increase of its binding to BIM. Then, when MCL-
1 was blocked with S63845, BIM was displaced and apoptosis
was then restored (Figure 5C). These findings explain why the
combination of sunitinib and S63845 synergize. Similarly as
before, BCL-2 and BCL-xL could not neutralize BIM after MCL-1
inhibition to prevent cell death.
We aimed to further investigate the other significant
synergy detected between sunitinib and the BCL-2 inhibitor
ABT-199. In contrast to MCL-1, BCL-2 expression slightly
decreased after exposing them to sunitinib (Figure 4C). We
followed the previous approach and immunoprecipitated BCL-
2, that was effectively pulled down (Figure 6A), and BIM
increase was observed after treatment with sunitinib in the
cell lysates (Figure 6B). BCL-2 was clearly detected in the
immunoprecipitated fraction and we could observe an increased
binding between BCL-2 and BIM in the SEM cells when
treated; and this interaction was displaced when sequentially
administering ABT-199 (Figure 6C). These results suggest that
the increase in BIM expression and the induction of apoptosis
after low-dose sunitinib treatment is neutralized preferentially by
BCL-2 and MCL-1. When sequentially inhibiting BCL-2 or MCL-
1 with the corresponding low-dose BH3 mimetic, BIM is then
displaced and the start of the apoptotic process is inevitable – the
other anti-apoptotic proteins cannot prevent it.
Pediatric BCP-ALL PDX Recapitulates
SEM Anti-apoptotic Adaptation
We next aimed to confirm these anti-apoptotic adaptations
using a PDX ALL sample derived from a pediatric BCP-ALL
patient with the same KMT2A-rearrangement (KMT2A/AFF1)
present in the SEM cell line (Benito et al., 2015). Following
the same experimental conditions, we shortly incubated these
cells with the same panel of targeted therapies and studied by
DBP the apoptotic induction in the blast population. Similarly as
previously described for the cell line, we observed a significant
1%priming increase with the BIM peptide after sunitinib
treatment but a modest increase with trametinib. The other
targeted therapies did not produce any perceptible apoptotic
changes (Figure 7). Interestingly, we also observed an increase
in priming with all three sensitizer peptides (BAD, HRK and
MS1) after sunitinib exposure and analogous protein expression
changes (Supplementary Figure 5), suggesting similar anti-
apoptotic adaptations as the ones observed in SEM cells
(Figure 7), which correlates with the akin genetic background.
DISCUSSION
Pediatric and young adult BCP-ALL patients present an overall
survival of 90% (Möricke et al., 2010; Pui et al., 2015).
However, the minor subset of R/R cases do worse and display
a poor outcome to therapy (Einsiedel et al., 2005; Ko et al.,
2010), consolidating ALL as the first cause of death for
pediatric cancer. Reinduction therapy for the most advanced
cases often include the same treatments previously used but
at a much higher concentrations (Raetz and Bhatla, 2012);
which is not only ineffective but also increases detrimental
secondary effects. There is a clear need for new and effective
treatments to improve the survival in those patients that do
not respond to actual chemotherapy regimens. Multiple targeted
therapies have been proposed as potential candidates to treat
different subtypes of BCP-ALL that present genetic targetable
vulnerabilities (Kuhlen et al., 2019). Chemotherapy relies on the
“one size fits all” concept in which all patients are treated in
the same way, but the inclusion of targeted therapies requires
a personalized medicine approach, where individual patient
tumors are first studied to find a driving oncogene to be
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FIGURE 5 | Increased binding of BIM to MCL-1 causes sunitinib and S63845 synergism. (A) Western blot analysis of the unbound fraction after MCL-1
immunoprecipitation. (B) Immunodetection of MCL-1 and BIM initial expression in cell lysates after 16 h of incubation with sunitinib 100 nM, and 2 h incubation with
S63845 100 nM in the specified conditions. Quantification of optical density for each protein was normalized to actin and fold-change was calculated comparing to
protein expression in the control condition. (C) Western blot of the immunoprecipitated fraction was used to study the interaction between MCL-1 and BIM after
treatment with sunitinib 100 nM and 2 h with S63845 100 nM. To quantify this binding, BIM optical density was normalized to MCL-1 optical density and fold-change
was calculated comparing to protein expression in the control condition. All results are expressed as the mean ± SEM of at least three biologically independent
replicates. Statistical significance was calculated using Student’s t-test compared to control condition and considering *p < 0.05 and **p < 0.01.
exploited pharmacologically. Despite recent advances in genetic
screening and current efforts to implement precision medicine
to treat pediatric patients (Ginsburg and Phillips, 2018), there
is a clear complication: childhood cancers present less genetic
alterations compared to adults. More precisely, they present a
very low frequency of somatic mutations, thus reducing the
number of predictive biomarkers and novel targeted therapies
(Gröbner et al., 2018).
The lack of genetic biomarkers is boosting functional assays
that directly expose cancer cells to selected potential treatment
to measure their efficacy. We and others have demonstrated
that DBP is a useful technology to screen and identify
effective treatments for many types of cancer, including pediatric
(Montero et al., 2015, 2017, 2019; Townsend et al., 2016; Pallis
et al., 2017; Grundy et al., 2018; Seyfried et al., 2019; Alcon
et al., 2020; Foley, 2020). We performed DBP in two BCP-
ALL cell lines by exposing them to potential targeted therapies
for this type of leukemia. From all the treatments tested, we
identified the MEK inhibitor trametinib as the most effective
in the young adult NALM-6 cell line. NALM-6 presents a
mutation in NRAS, and downstream activation of the MAPK
pathway, that may explain its sensitivity to trametinib (Irving
et al., 2014). In another pediatric BCP-ALL cell line, named
SEM, DBP predicted trametinib and sunitinib effectiveness
that was later confirmed by cell death measurements – the
latter was particularly active as single agent. Sunitinib has
been proposed as a potential candidate to treat FLT3-driven
hematological malignancies (Ikezoe et al., 2006), an alteration
that is present in the SEM cell line (Brown et al., 2005;
Gu et al., 2011). These results demonstrate DBP’s capacity to
functionally identify effective targeted agents without requiring
genetic information, which we believe would help personalize
R/R BCP-ALL patients treatment.
Since the approval of venetoclax for chronic lymphocytic
leukemia, BH3 mimetics have bloomed as potential treatments
for multiple types of cancer, predominantly hematological
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FIGURE 6 | BCL-2 binds to BIM after sunitinib treatment promoting synergy with ABT-199. (A) Western blot analysis of the unbound fraction after BCL-2
immunoprecipitation. (B) Immunodetection of BCL-2 and BIM initial expression in cell lysates after 16 h of incubation with sunitinib 100 nM, and 4 h incubation with
ABT-199 10 nM. Quantification of optical density for each protein was normalized to actin and fold-change was calculated comparing to protein expression in the
control condition. (C) Western blot of the immunoprecipitated fraction to study the interaction between BCL-2 and BIM after sunitinib 100 nM treatment, and 4 h
with ABT-199 10 nM. To quantify this binding, BIM optical density was normalized to BCL-2 optical density and fold-change was calculated comparing to protein
expression in the control condition. All results are expressed as the mean ± SEM of at least three biologically independent replicates. Statistical significance was
calculated using Student’s t-test compared to control condition and considering *p < 0.05 and **p < 0.01.
(Valentin et al., 2018). Despite impressive experimental and
clinical results as single agents, increasing evidence showed that
BH3 mimetics real potential is enhancing other anti-cancer
agents, both conventional chemotherapy and targeted (Montero
and Letai, 2018; Oudenaarden et al., 2018; Savona and Wei,
2019; Lin et al., 2020). Numerous studies have demonstrated
that cancer cells often rely on anti-apoptotic proteins to acquire
resistance to therapy, and BH3 mimetics can effectively block
these adaptations (Hata et al., 2015; Maji et al., 2018). However,
with these new therapeutic strategies we face the same problem
described for targeted therapies: when and how to correctly
use these BH3 mimetics in the clinic. We previously described
that DBP can identify anti-apoptotic adaptations after treatment
and guide effective combinations with BH3 mimetics to boost
therapy’s potency (Montero et al., 2019; Alcon et al., 2020).
When we applied it to BCP-ALL, we found that trametinib
as single agent only produced a modest cytotoxic effect on
NALM-6 cells, but when sequentially combined with the MCL-
1 inhibitor S63845, it reached an almost complete elimination
of these cancer cells. Similarly, sunitinib synergized with ABT-
199 and S63845 in the SEM cell line, despite reducing 10-
fold its concentration. Importantly, all these combinations were
anticipated by DBP after only a short incubation with the targeted
therapy, demonstrating the utility of this functional assay as
predictive biomarker for synergistic combinations of anti-cancer
agents with BH3 mimetics.
Anti-apoptotic adaptations in response to therapy may appear
by multiple cellular processes. When we analyzed the BCL-2
family of proteins after trametinib and sunitinib treatment, in
both cases we observed a significant increase of pro-apoptotic
BIM expression, priming cells for apoptosis. Its stabilization
after kinase inhibitors use has been previously reported and
related to the loss of ERK1/2 phosphorylation (Cragg et al.,
2008; Tan et al., 2013; Elgendy et al., 2017), as we confirmed
for both agents. Some reports also point out that sunitinib
may cause its accumulation by inhibiting STAT3 and AKT
(Xin et al., 2009; Yang et al., 2010). Interestingly, changes
in anti-apoptotic BCL-2 family members were very different
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FIGURE 7 | PDX cells presenting KMT2A rearrangement show a similar DBP profile as the SEM cells. DBP with BIM BH3, BAD BH3, HRK BH3, and NOXA BH3
peptides after 16 h of incubation with 1,000 nM imatinib, 100 nM dasatinib, 1,000 nM sunitinib, 100 nM trametinib, 100 nM ruxolitinib and 1,000 nM ibrutinib in PDX
cells. 1%priming stands for the difference in %priming between treatment and control condition. All results are expressed as the mean ± standard deviation of two
technical replicates.
when exposed to both kinase inhibitors. Trametinib increased
MCL-1 expression to neutralize BIM, as previously described
(Korfi et al., 2016). Although MEK inhibition was reported to
enhance BCL-2/xL inhibitors cell death induction in BCP-ALL
by Korfi and colleagues, as we also confirmed, as far as we know
this is the first time that it is shown that trametinib strongly
synergizes with MCL-1 inhibition in this disease. In contrast,
sunitinib promoted BIM binding to BCL-2 and MCL-1, despite
the overall expression decrease of these pro-survival proteins.
Even if the adaptation mechanism was different, we could also
overcome it by sequentially adding a BH3 mimetics, venetoclax
or S63845, to this targeted agent, demonstrating the therapeutic
potential of these molecules. We validated these results using
a pediatric BCP-ALL PDX sample obtained from a patient
presenting the same KMT2A rearrangement as the SEM cell line
(Bhimani et al., 2020), detecting similar therapeutic responses.
DBP identified sunitinib as the most effective agent inducing
apoptotic priming; correlating with the results observed in the
SEM cell line, but contrasting to NALM-6 cells that present a
different genetic background. Furthermore, we observed similar
anti-apoptotic adaptations when exposed to this kinase inhibitor,
predicting that low-dose sunitinib combination with ABT-199
or S63845 could enhance the therapeutic effect for this patient.
Altogether, these results demonstrate that DBP could be used
as companion diagnostic tool to stratify R/R BCP-ALL cases
and identify the optimal combination of targeted therapies with
BH3 mimetics to maximize anti-cancer efficacy while decreasing
undesired secondary effects. Although sunitinib was previously
characterized as a potential treatment for BCP-ALL as a FLT3
inhibitor (Griffith et al., 2016), to our knowledge this is the first
time that it is described in combination with BH3 mimetics to
treat this disease.
In summary, these findings could represent three new
potential therapeutic strategies for BCP-ALL. Taking into
consideration that venetoclax is already approved for clinical
use and that multiple MCL-1 inhibitors are currently explored
in clinical trials, we believe that these synergistic combinations
that we here describe could likely improve R/R BCP-ALL patient
treatment and clinical outcomes.
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Supplementary Figure 1 | (A) ROC curve analysis using the values of
1%priming in NALM-6 and SEM cell lines establishing 10% as the cell death
threshold for responders and non-responders. (B) Correlation between
1%priming and %cell death analyses.
Supplementary Figure 2 | (A) Western blot analysis of phospho-ERK1/2 and
phospho-BIM in NALM-6 cell line after 16 h of treatment with trametinib 100 nM.
(B) Western blot analysis of BAK and BAX in NALM-6 cell line after 16 h of
treatment with trametinib 100 nM. Quantification of optical density for each protein
was normalized to actin, and fold-change was calculated comparing to protein
expression in the control condition. All results are expressed as the mean ± SEM
of at least three biologically independent replicates. Statistical significance was
calculated using Student’s t-test compared to control condition and considering
∗p < 0.05 and ∗∗p < 0.01.
Supplementary Figure 3 | ABT-199 and S63845 induce cytotoxicity in the SEM
cell line. Cytotoxicity expressed as percentage of dead cells after 72 h of treatment
with 100 nM ABT-199 and 1,000 nM S63845, as assessed by an Annexin V/DAPI
staining. All results are expressed as the mean ± SEM of at least three biologically
independent replicates. Statistical significance was calculated using Student’s
t-test compared to control condition and considering ∗p < 0.05 and ∗∗p < 0.01.
Supplementary Figure 4 | (A) Western blot analysis of phospho-ERK1/2 and
phospho-BIM in the SEM cell line after 16 h of treatment with sunitinib 100 nM
and 1,000 nM. (B) Western blot analysis of BAK and BAX in SEM cell line after
16 h of treatment with sunitinib 100 nM and 1,000 nM. Quantification of optical
density for each protein was normalized to actin, and fold-change was calculated
comparing to protein expression in the control condition. All results are expressed
as the mean ± SEM of at least three biologically independent replicates. Statistical
significance was calculated using Student’s t-test compared to control condition
and considering ∗p < 0.05 and ∗∗p < 0.01.
Supplementary Figure 5 | BCL-2 family of proteins expression in BCP-ALL PDX
cells after sunitinib treatment. Western blot analysis for anti-apoptotic and BIM
proteins in BCP-ALL PDX cells after 16 h of treatment with sunitinib 100 nM and
sunitinib 1,000 nM. Quantification of optical density for each protein was
normalized to actin, and fold-change was calculated comparing to protein
expression in the control condition.
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